Frontline therapy for multiple myeloma (MM) in real-world clinical practice: Results from the third interim analysis of the multinational, non-interventional, observational EMMOS study
2015
patients, serum lactic dehydrogenase was elevated (>300 U/L) in eight patients and found to correlate with the serum concentrations of 2-microglobuline, hemoglobin and creatinine. Patients with values below 300 U/L had a median survival time of 88 months (Mean: 87.8, SD: 43.8, CV: 0.5) compared to 90 months (Mean: 87 months, SD: 42.3, CV: 0.5) for those with levels above 300 U/L. Conclusion: Serum lactic dehydrogenase at diagnosis, thus, had no prognostic information in multiple myeloma when related to overall survival. 2. Multiple Myeloma Therapy in Newly Diagnosed Patients including Transplantation
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
2
Citations
NaN
KQI